abstract |
The invention relates to methods for treating osteogenesis imperfecta in a patient by administering to the patient a therapeutically effective amount of an antibody or its antigen-binding fragment that binds specifically to the transforming growth factor beta TGFβ1, TGFβ2 and TGFβ3 and neutralizes it. |